Sage Journals: Discover world-class research

Open access

Research article

First published 2021

Dynamics of serum concentrations of antibodies to infliximab: a new approach for predicting secondary loss of response in inflammatory bowel diseases

Melina K. Grasmeier, Anna F. Langmann, Peter Langmann [...]

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2023

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response

Eun Sil Kim, Yiyoung Kwon, Yon Ho Choe [...]

Therapeutic Advances in Gastroenterology

Open access

Review article

First published 2019

Infliximab in inflammatory bowel disease

Konstantinos Papamichael, Steve Lin, Matthew Moore [...]

Sage Open Chronic Disease

Free access

Research article

First published 2015-11

Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature

Mandy Perry, Claire Bewshea, Richard Brown [...]

Annals of Clinical Biochemistry: International Journal of Laboratory Medicine

Free access

Letter

First published 2007-7

Re-Induction as a Possible Alternative Modality of Dose Escalation of Infliximab: A Prospective Evaluation in a Small Series of Psoriatic Patients

N. Cassano, A. Puglisi Guerra, C. Malara [...]

International Journal of Immunopathology and Pharmacology

Open access

Research article

First published 2022

Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease

Ashish Srinivasan, Robert Gilmore, Daniel van Langenberg [...]

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2019

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado [...]

Therapeutic Advances in Gastroenterology

Open access

Research article

First published 2023

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

Rosanne W. Meijboom, Helga Gardarsdottir, Matthijs L. Becker [...]

Therapeutic Advances in Gastroenterology

Free access

Research article

First published 2010-1

Long-Term Anti-TNF-α Treatments Reverse the Endothelial Dysfunction in Rheumatoid Arthritis: The Biological Coherence between Synovial and Endothelial Inflammation

A. Capria, D. De Nardo, F.R. Baffetti [...]

International Journal of Immunopathology and Pharmacology

Retricted access

Review article

First published 2000-6

Treatment Options for Rheumatoid Arthritis: Celecoxib,Leflunomide,Etanercept,and Infliximab

Brigitte T Luong, Barbara S Chong, Dionne M Lowder

Annals of Pharmacotherapy

Search results